#letermovir

Anagrelide 0.5 mg is an effective medication for managing high platelet counts, especially in conditions like essential thrombocythemia (ET). By reducing platelet production in the bone marrow, Anagrelide helps lower the risk of serious complications such as strokes and heart attacks.In Impomed Healthcare plays a crucial role in providing access to Anagrelide 0.5 mg in India, ensuring patients receive this important treatment. With a focus on quality and patient care, Impomed collaborates with healthcare providers to make this medication widely available. If you or someone you know is facing high platelet levels, consulting with a healthcare provider about Anagrelide 0.5 mg can be a vital step toward better health.

Letermovir Sebagai Obat Baru Antiviral pada Cytomegalovirus

Farmasetika.com – Letermovir (sebelumnya dikenal sebagai AIC246) adalah agen anti-CMÞ1V baru yang sangat potensial dengan mekanisme tindakan baru yang menargetkan subunit terminologi virus pUL56, (Lishka et al., 2010; Goldner et al., 2011) komponen dari terminase Kompleks yang terlibat dalam pembelahan DNA virus yang tidak memiliki target enzim setara dalam tubuh manusia.

Dengan demikian,…

by Greziel Guanzon

Trade Name: Prevymis

Routes of Administration: Oral

Tablet: 240 mg, 480mg

Solution for injection: 20mg/mL  (vials contain 240mg/12mL or 480mg/24ml)

1. What is Letermovir?

An antiviral drug for the treatment of cytomegalovirus (CMV) infections. This drug is orally bioavailable and an inhibitor of the subunit of the viral terminase complex of cytomegalovirus (CMV).

Upon oral administration, the drug binds to the viral terminase complex of CMV and prevents the cleavage of concemeric DNA into monomeric length DNA. Letermovir interfere with viral DNA processing and subsequent viral DNA packaging into procapsids that results to CMV replication being blocked and its infection prevented.  

    Letermovir is used in the prophylaxis of cytomegalovirus (CMV) infection in allogenic hematopoietic stem cell transplant patients.  

      Letermovir has a priority and orphan drug status from FDA and is marketed as Prevymis.

Sources:

Letermovir, Obat Antivirus Baru dari Merck Sukses di Uji Klinik Tahap Akhir

farmasetika.com – MSD, yang dikenal sebagai Merck di AS, merilis berita tentang suksesnya mencapai endpoint utama dalam uji klinik tahap III yang mengevaluasi keamanan dan kemanjuran obat antivirus letermovir.

Letermovir adalah pengobatan sekali sehari yang telah diteliti untuk diberikan baik sebagai tablet oral atau melalui formulasi injeksi IV. Letermovir merupakan anggota dari kelas baru…

Letermovir, MK 8828, AIC 246

2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid

 CAS 917389-32-3

Letermovir; UNII-1H09Y5WO1F; AIC-246; 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic acid;…